Create Free Account

By creating account you will get access to hot stocks & personalised emails

Dimerix Ltd

Healthcare AU DXB

0.32AUD
-0.02(5.88%)

Last update at 2024-12-19T05:11:00Z

Day Range

0.320.34
LowHigh

52 Week Range

0.160.67
LowHigh

Fundamentals

  • Previous Close 0.34
  • Market Cap200.82M
  • Volume2792487
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-17.06881M
  • Revenue TTM0.58M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 8.98M
  • Diluted EPS TTM-0.04

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -13.80282M -10.49058M -6.37173M -4.49415M -2.88622M
Minority interest - - - - -
Net income -13.80282M -10.49295M -6.37023M -4.49145M -1.43415M
Selling general administrative 2.17M 2.39M 1.44M 1.30M 1.46M
Selling and marketing expenses 0.07M - - - -
Gross profit 8.98M - - - 1.45M
Reconciled depreciation 0.06M 0.05M 0.04M 0.01M 0.00468M
Ebit -22.82334M -16.95640M -10.92817M -6.91839M -4.33829M
Ebitda -22.76733M -16.90586M -10.88357M -6.90486M -4.33361M
Depreciation and amortization 0.06M 0.05M 0.04M 0.01M 0.00468M
Non operating income net other - - - - -
Operating income -13.83961M -16.95640M -10.92817M -6.91839M -4.33829M
Other operating expenses 22.82M 16.96M 10.93M 6.92M 4.34M
Interest expense - 0.00237M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.04M 0.00237M 0.00151M 0.00270M 0.02M
Net interest income 0.04M 0.00237M 0.00151M 0.00270M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.03679M 0.00237M -0.00151M -0.00270M -1.45207M
Total revenue 8.98M 0.00237M 0.00151M 0.00270M 0.02M
Total operating expenses 22.82M 16.96M 10.93M 6.92M 4.34M
Cost of revenue - - - - -
Total other income expense net 8.98M 6.47M 4.56M 2.42M 1.45M
Discontinued operations - - - - -
Net income from continuing ops -13.80282M -10.49058M -6.37173M -4.49415M -2.88622M
Net income applicable to common shares -13.80282M -10.49058M -6.37173M -4.49415M -2.88622M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 32.08M 17.76M 16.50M 9.42M 10.39M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.26M 0.02M 0.07M 0.04M 0.03M
Total liab 13.89M 11.79M 2.07M 7.95M 2.63M
Total stockholder equity 18.19M 5.96M 14.42M 1.47M 7.76M
Deferred long term liab - - - - -
Other current liab 2.40M 6.62M 0.91M 5.43M 1.48M
Common stock 83.38M 55.49M 50.90M 28.39M 28.34M
Capital stock 83.38M 55.49M 50.90M 28.39M 28.34M
Retained earnings -69.17605M -52.10097M -38.29815M -27.80757M -21.43583M
Other liab - 0.04M 0.03M - -
Good will - - - - -
Other assets - - - - -
Cash 22.14M 7.99M 9.63M 5.25M 7.79M
Cash and equivalents - 7.99M 9.63M 5.25M 7.79M
Total current liabilities 3.36M 11.76M 2.02M 7.95M 2.63M
Current deferred revenue 0.57M -5.95781M -0.05212M -5.09309M -1.09433M
Net debt -21.99178M -2.03398M -9.55666M -0.15700M -6.69137M
Short term debt 0.08M 5.96M 0.05M 5.09M 1.09M
Short long term debt - 5.94M - 5.05M 1.06M
Short long term debt total 0.15M 5.96M 0.07M 5.09M 1.09M
Other stockholder equity - -3.38840M -12.59699M -0.58155M -6.90828M
Property plant equipment - 0.00641M 0.00861M 0.00142M 0.00123M
Total current assets 31.92M 17.75M 16.49M 9.42M 10.39M
Long term investments - - - - -
Net tangible assets - 5.96M 14.42M 1.47M 7.76M
Short term investments - - - - -
Net receivables 9.52M 9.55M 6.39M 4.01M 2.46M
Long term debt - - - - -
Inventory - 0.18M 0.40M 0.12M 0.11M
Accounts payable 0.31M 5.14M 1.11M 2.52M 1.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.98M 2.57M 1.83M 0.89M 0.85M
Additional paid in capital - - - - -
Common stock total equity - - - - 28.34M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00641M -0.00861M -0.00142M -0.00123M
Deferred long term asset charges - - - - -
Non current assets total 0.16M 0.00641M 0.00861M 0.00142M 0.00123M
Capital lease obligations 0.15M 0.02M 0.07M 0.04M 0.03M
Long term debt total - 0.00000M 0.02M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.00230M -0.01061M 0.00438M - -0.00691M
Change to liabilities 3.64M -0.92150M 1.28M 0.79M 0.35M
Total cashflows from investing activities -0.00230M -0.01061M 0.00438M 0.00438M -0.00691M
Net borrowings 6.29M -1.74743M 3.89M 1.01M 1.01M
Total cash from financing activities 11.07M 17.69M 3.83M 8.91M 8.91M
Change to operating activities 0.06M -0.24890M 0.02M 0.00370M -0.04719M
Net income -13.80282M -10.49058M -6.37173M -4.49415M -1.43415M
Change in cash -1.63796M 4.38M -2.53561M 4.22M -2.72104M
Begin period cash flow 9.63M 5.25M 7.79M 3.56M 6.28M
End period cash flow 7.99M 9.63M 5.25M 7.79M 3.56M
Total cash from operating activities -12.72866M -13.43594M -6.36044M -4.72148M -11.66189M
Issuance of capital stock 8.72M 20.68M 0.04M 8.34M -
Depreciation 0.06M 0.05M 0.04M 0.01M 0.00468M
Other cashflows from investing activities - 0.00000M 0.01M - -
Dividends paid - 0.00140M 1.24M 1.07M -
Change to inventory - - - - -
Change to account receivables -3.16842M -2.33708M -1.54373M -1.18911M -0.37147M
Sale purchase of stock -0.44461M -1.24001M -1.24001M -0.44141M -0.44141M
Other cashflows from financing activities 2.79M -0.04743M 4.85M 1.01M 1.01M
Change to netincome 0.49M 0.51M 0.20M 0.16M 0.19M
Capital expenditures 0.00230M 0.01M 0.00957M 0.00957M 0.00691M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.16842M -2.33708M -1.54373M -1.18911M 1.09M
Stock based compensation 0.07M 0.13M 0.04M 0.13M -
Other non cash items 1.02M -2.99590M -0.03331M -0.24086M 2.88M
Free cash flow -12.73096M -13.44655M -6.37001M -4.72148M -11.66880M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DXB
Dimerix Ltd		 -0.02 5.88% 0.32 - - 344.18 10.74 - -1.9424
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

Dimerix Ltd

425 Smith Street, Fitzroy, VIC, Australia, 3065

Key Executives

Name Title Year Born
Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D. CEO, MD & Director NA
Dr. Ashish Soman M.B.A., M.D., MBBS Chief Medical Officer NA
Mr. Hamish George B.Com., C.A. CFO & Company Sec. NA
Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D. Chief Scientific Advisor NA
Ms. Elizabeth McCall B.Com(Hons), B.Juris, BJURIS, GAICD, L.L.B., LLB. Bus. Devel. Officer NA
Mr. Hamish George B.Com., C.A. CFO & Company Secretary NA
Dr. David Everett Fuller BPharm, M.D., MBBS Chief Medical Officer 1964
Mr. Robert Shepherd Chief Commercialisation Officer NA
Mr. Hamish George B.Com., C.A. CFO & Company Secretary NA
Dr. David Everett Fuller BPharm, M.D., MBBS Chief Medical Officer 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.